TABLE III.
Germinoma Patients' Tumor Characteristics and Treatment Outcome
| Patient number | Sex/age (yrs) | Site | Metastases | β-hcg blood/CSF | Surgery | Chemotherapy response | Status |
|---|---|---|---|---|---|---|---|
| 1 | M/17.7 | Pineal | Ventricle CSF | NL/NL | Biopsy | PR | PFS 63 mos |
| 3 | M/15.1 | Thalamic | NL/NL | 75% resection | PR | PFS 70 mos | |
| 4 | M/15.5 | Para-pineal | NL/NL | 80% resection | CR | PFS 73 mos | |
| 6 | M/15.6 | Pineal | NL/NL | Biopsy | CR | PFS 65 mos | |
| 7 | F/11.1 | Suprasellar | CSF spine | NL/NL | Biopsy | PR | PFS 66 mos |
| 8 | M/13.1 | Pineal | CPA | NL/NL | Partial removal | PR | PFS 71 mos |
| 11 | M/15.2 | Bilat basal ganglia | 11/21 mIU/ml | Biopsy | SD | PFS 64 mos | |
| 13 | M/9.5 | Pineal | NL/NL | GTR | Not Eval. | PFS 68 mos | |
| 17 | M/11.6 | Basal ganglia | NL/8.2 mIU/ml | Biopsy | CR | PFS 67 mos | |
| 18 | M/15.2 | Thalamic–pineal | NL/NL | Biopsy | PR | PFS 66 mos | |
| 19 | M/15.6 | Pineal-suprasellar | Spine | NL/6.9 mIU/ml | Biopsy | PR* | PFS 61 mos |
| 21 | F/10.1 | Suprasellar | NL/7.6 | Partial removal | CR** | PFS 10 mos | |
| OS ** 56 mos |
Yrs, years; HCG, beta subunit of human chorionic gonadotrophin; CSF, cerebrospinal fluid; M, male; F, female; CPA, cerebellar pontine angle; NL, normal; CR, complete response; PR, partial response; SD, stable disease; Eval, evaluable; PFS, progression-free survival; mos, months; OS, overall survival.
All patients received radiation therapy as per protocol except:
*
Patient 19 who was treated as a CR (central review ranked response as PR)
**
Patient 21 who did not receive radiation (parents' request), developed PD at 10 mos, then received neuraxis radiation and was progression-free at 56 mos.